Research Article

Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect

Table 2

Partial correlation of serum TRAIL prior to infliximab infusion (at time 0) with selected continuous variables adjusted for age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity, and hypertension) in 30 patients with ankylosing spondylitis.

VariableTRAIL (time 0)

Age at the onset of symptoms−0.0260.90
Disease duration*−0.0110.96
BMI*0.0420.84
Systolic blood pressure*0.0390.85
Diastolic blood pressure*0.0870.66
BASDAI*0.0890.66
VAS spinal pain*0.1350.50
ESR* (natural-log-transformed)0.0180.93
CRP* (natural-log-transformed)−0.0800.69
ESR** (natural-log-transformed)0.0450.83
CRP** (natural-log-transformed)0.0110.96
(natural-log-transformed)0.3930.04
HDL cholesterol* (natural-log-transformed)−0.1110.58
(natural-log-transformed)0.4520.02
Atherogenic index* (total cholesterol/HDL)−0.1800.38
Triglycerides* (natural-log-transformed)0.1850.36
Serum glucose* (natural-log-transformed)−0.0920.65
HOMA-IR at time 0.3680.06
QUICKI at time 0.4400.02
Resistin at time 00.4270.05
Adiponectin at time 0−0.0090.97
Leptin at time 00.0690.74
Visfatin at time 00.0480.81
Angpt-2 at time 0−0.0550.79
Apelin at time 00.3730.06
ADMA at time 0−0.0580.78
Gelsolin at time 00.1730.39
OPN at time 00.3720.06
RBP-4 at time 00.3180.11
Osteoprotegerin at time 00.0440.83

At the time of the study. At the time of disease diagnosis.
ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin 2; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; LDL: low-density lipoprotein; OPN: osteopontin; QUICKI: quantitative insulin sensitivity check index; RBP-4: retinol-binding protein 4; VAS: visual analogue scale.